Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FRSW 117

Drug Profile

FRSW 117

Alternative Names: FRSW-117; PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein

Latest Information Update: 13 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Gensciences
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Immunoglobulin Fc fragments; Recombinant fusion proteins
  • Mechanism of Action Factor VIII replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Haemophilia A

Most Recent Events

  • 27 Dec 2023 Phase-III clinical trials in Haemophilia A (In adolescents, Treatment-experienced, In adults) in China (Parenteral) (NCT06142552)
  • 09 Dec 2023 Preliminary efficacy, adverse events, pharmacodynamics and pharmacokinetics data from a phase II trial in Haemophilia A presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 27 Nov 2023 Jiangsu Gensciences plans a phase III trial in Hemophilia A (In adolescents, In adults) in China [Parenteral,Injection] in November 2023 (NCT06142552)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top